HANGZHOU, China, September 26, 2022 /PRNewswire/ — CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has entered into a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy.
The collaboration will leverage both parties’ technologies and expertise, and integrate R&D, manufacturing and marketing capabilities to develop CAR-iMAC clinical products for solid tumors.
“Innovation and delivering the best products that benefit patients are the core values that CellOrigin Biotech and Qilu Pharma both value,” said Dr. Jin Zhangco-founder of CellOrigin Biotech and principal investigator of Zhejiang University, one of the best universities in China. “That’s what brings us together.”
“We are very pleased to collaborate with Qilu Pharma due to its prestige in the Chinese pharmaceutical industry, as well as its formidable track record in drug development,” said Dr. Jiansong Tong, CEO of CellOrigin Biotech. “In the meantime, we will continue to seek other potential collaborators to jointly develop our innovative anti-tumor CAR-iMac cell products.”
“CellOrigin Biotech is a start-up company created by a group of outstanding scientists who have considerable experience in both research and development and cGMP manufacturing. It has been focused on developing innovative technologies in the field cell therapy and creating a valuable product portfolio. It is an ideal strategic partner for new cell therapies, and it is a pleasure for us to collaborate with such a large biotech company,” said Qilu. Pharmaceuticals.
About CellOrigin Biotech
CellOriginBiotech (Hangzhou) Co., Ltd. is dedicated to the development of immune cell therapies derived from genetically modified pluripotent stem cells (iPSC) (such as macrophages, NK cells), with its own exclusive intellectual property. The founders are experienced leaders of Zhejiang University, Harvard University and the world’s largest pharmaceutical and biotechnology companies. They apply state-of-the-art technologies in iPSC editing and differentiation to immune cells to provide novel off-the-shelf allogeneic cell therapies for the treatment of cancer patients worldwide.
About Qilu Pharma
Qilu Pharma is one of the leading vertically integrated pharmaceutical companies in China focused on the discovery, development, manufacture and commercialization of innovative drugs. With a diverse pipeline of innovative therapies, 10 manufacturing sites and more than 36,000 employees worldwide, Qilu is dedicated to transforming scientific innovation through in-house R&D across 5 US-based R&D platforms (Seattle, WA, Boston MA, California from San Francisco) and China (Shanghai, jinan), and global external partnership in healthcare solutions to address unmet medical needs. To date, Qilu has launched more than 200 products with more than 30 “First to Launch” products in China and 3 “D181 launch” products in the United States with approximately US$5.2 billion revenue in 2021. For more information, please visit http:en.qilu-pharma.com.
SOURCECellOrigin
